Auna releases transcript of Q2 2026 earnings conference call

Auna discussed Q2 2026 results on its earnings call with Executive Chairman and President Suso Zamora, CFO Gisele Remy, and EVP Lorenzo Massart.

• Revenue rose 9% on volume growth and a higher-complexity mix; adjusted EBITDA fell 9% FX-neutral on pressures in Mexico and Colombia, and Peru billing penalties.
• Leverage improved to 3.6x; net cash from operations reached PEN 441 million in H1; free cash flow increased 181% year-over-year.
• Mexico surgeries rose 7% sequentially; oncology chemo and radiotherapy rose 20% sequentially; revenue increased 4% as adjusted EBITDA fell 16% year-over-year.
• The company reaffirmed 2026 revenue guidance of about 12% FX-neutral growth and adjusted EBITDA growth toward the low end of 10%-14% excluding Peru penalties.